| BALL |
Report |
Comparable diluted EPS |
BEAT |
pred ~$1.03 vs. cons $0.99 |
MEDIUM |
| BALL |
Report |
Comparable operating earnings |
BEAT |
pred ~$446M vs. cons ~$440M |
MEDIUM |
| BALL |
Report |
Net sales |
IN-LINE |
pred ~$3.72B vs. cons $3.69B |
MEDIUM |
| BALL |
Guide |
Comparable EPS growth |
LOWER |
guide ~10%+ vs. cons 11.8% (FY2026) |
MEDIUM |
| BALL |
Guide |
Free cash flow |
LOWER |
guide >$900M vs. cons ~$925M (FY2026) |
MEDIUM |
| BALL |
Guide |
Implied comparable EPS |
LOWER |
guide ~$1.03 vs. cons $1.06 (2026Q3) |
LOW |
| BALL |
Guide |
Share repurchases |
UNCHANGED |
guide ≥$600M vs. cons ~$600M (FY2026) |
HIGH |
| BALL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.2% |
— |
MEDIUM |
| BALL |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
A predicted ~$0.04 Q2 EPS beat versus consensus is likely offset by an implicit ~$0.03 Q3 EPS cut from start-up costs, while FY2026 EPS growth remains ~10%+ versus the Street's 11.8%; unchanged cash-flow and buyback targets limit upward revisions and should keep estimates drifting lower after the report. |
MEDIUM |